ComparisonDiff cost95% credible intervalDiff QALY95% credible interval
ADA–DMARDs26,90025,10028,6000.780.341.28
ETN–DMARDs33,70031,70035,9000.880.381.47
IFX–DMARDs18,40015,10020,7000.490.210.82
RTX–DMARDs20,40017,50023,5000.960.421.60
ABT–DMARDs44,10041,30046,9001.140.511.86
ADA–RTX6,5003,2009,800−0.18−0.470.05
ETN–RTX13,3009,90016,800−0.09−0.380.16
IFX–RTX−2,000−5,9001,600−0.48−0.87−0.16
ABT–RTX23,60019,60027,5000.18−0.090.50
ADA–ABT−17,200−20,300−14,100−0.36−0.72−0.10
ETN–ABT−10,400−13,500−7,100−0.27−0.59−0.03
IFX–ABT−25,600−29,900−22,100−0.65−1.12−0.26
ADA–ETN−6,800−9,400−4,200−0.09−0.320.10
ADA–IFX8,4005,70012,0000.290.070.56
ETN–IFX15,30012,30018,9000.390.140.72

Diff, difference in.

Difference calculated by subtracting the value for the strategy named second from the value for the strategy named first.

From: Appendix 14, Scenario analyses

Cover of Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.14.
Malottki K, Barton P, Tsourapas A, et al.
Southampton (UK): NIHR Journals Library; 2011 Mar.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.